



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/616,622	07/10/2003	Daniel M. Lafontaine	29985/02-332	3366

57726 7590 02/05/2007  
MILLER, MATTHIAS & HULL  
ONE NORTH FRANKLIN STREET  
SUITE 2350  
CHICAGO, IL 60606

EXAMINER
----------

YABUT, DIANE D

ART UNIT	PAPER NUMBER
----------	--------------

3734

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	02/05/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

# Office Action Summary

Application No.

10/616,622

Applicant(s)

LAFONTAINE, DANIEL M.

Examiner

Diane Yabut

Art Unit

3734

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 24 November 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-10, 13 and 15-41 is/are pending in the application:
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-10, 13 and 15-41 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 20 November 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- ☐ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_.
- ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- ☐ Notice of Informal Patent Application
- ☐ Other: \_\_\_\_\_.

### DETAILED ACTION

This action is in response to applicant's amendment received on 24 November 2006.

Examiner acknowledges the corrections made to the specification and the amendments made to the claims.

### *Claim Rejections - 35 USC § 103*

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 1-10, 13, and 15-39 are rejected under 35 U.S.C. 103(a) as being unpatentable over **Lafontaine et al.** (U.S. Patent No. **5,964,782**) in view of **Redmond et al.** (U.S. Patent No. **6,334,865**).

Claims 1, 26, 33, and 34: Lafontaine et al. discloses a closure device comprising an elongate delivery member **334** having a distal end and a proximal end and a closure component **344** removably connected to the distal end of the delivery member, the closure component including a collapsible backing, movable between a non-collapsed position and a collapsed position, and a plurality of fibrous tissue engaging members disposed on the backing and oriented in a non-engaging orientation when traveling in a distal direction and in an engaging orientation when traveling in a proximal direction, the fibrous tissue engaging members entangling the backing when the backing is in the collapsed position (Figure 34A and col. 17, lines 39-51). Lafontaine et al. also discloses

Art Unit: 3734

a method of closing an opening **332** in a body comprising inserting distally through the opening a closure component **344** having collapsible pile backing with pile engaging hooks and tissue engaging hooks disposed thereon, withdrawing the closure component **344** proximally relative to the opening such that the tissue engaging hooks engage tissue adjacent the opening, and collapsing the collapsible pile backing so the pile engaging hooks engage portions of the pile backing (col. 17, lines 22-50).

Lafontaine discloses the claimed device except for the backing having a generally conical shape with a center portion of the backing distally spaced from a periphery of the backing, and the backing center portion being collapsed proximally toward the backing periphery to have a generally disc shape.

Redmond et al. teaches a backing **26** having a generally conical shape with a center portion of the backing distally spaced from a periphery of the backing, and the backing center portion being collapsed proximally toward the backing periphery to have a generally disc shape which is retained in the collapsed position by engaging hooks (Figures 1-3). It would have been obvious to one of ordinary skill in the art at the time of invention to provide the conical shaped-backing that collapses proximally into a disc shape, as taught by Redmond et al., to Lafontaine et al. since it was known in the art that closure devices with conical, elongate configurations more conveniently fit and maneuver through delivery sheaths and body lumens, and that collapsing to a disc shape offers more surface area coverage for closure of a body lumen.

Claims 2,3, and 35: Lafontaine et al. discloses a backing formed in a generally elongate conformation, along a generally longitudinal axis of the backing, in the non-

Art Unit: 3734

collapsed position, and the backing collapsed generally along the longitudinal axis when in the collapsed position (Figures 35 and 37B).

Claims 4,5,36 and 37: Lafontaine et al. discloses the fibrous tissue engaging members forming proximally facing hooks that are spaced along the backing from a proximal portion thereof to a distal portion thereof when the backing is in the non-collapsed position (Figure 35).

Claims 6 and 38: Lafontaine et al. discloses the hooks entangle in the backing located proximal of the hooks as the backing moves from the non-collapsed position to the collapsed position (col. 17, lines 38-43 and col. 18, lines 24-29).

Claims 7 and 39: Lafontaine et al. discloses the body cavity 332 is defined by generally smooth tissue and has fibrous tissue proximal thereof and wherein at least a subset of the plurality of hooks 4 are oriented to engage the fibrous tissue as the hooks travel in a proximal direction relative to the fibrous tissue (Figures 34A-34C and col. 17, lines 27-42).

Claims 8-10: Lafontaine et al. discloses the claimed device, including a closure component having a first row of hooks disposed about a proximal end thereof including tissue piercing hooks that pierce tissue and pass along the generally smooth tissue without engaging the generally smooth tissue and engage the fibrous tissue as the closure component is moved proximally relative thereto (Figure 34A-34C and col. 19, lines 54-67), except for the closure component being generally conical.

Redmond et al. teaches the closure component being generally conical (Figures 1-3) and it would have been obvious to one of ordinary skill in the art at the time of

Art Unit: 3734

invention to provide a conical closure component, as taught by Redmond et al., to Lafontaine et al. since it was known in the art that closure devices with conical, elongate configurations more conveniently fit and maneuver through delivery sheaths and body lumens

Claim 13: Lafontaine et al. discloses an active actuator **388** having a distal engaging end disconnectably connecting the closure component to the delivery member and a proximal end receiving an actuation input and actuating the distal engaging end to release the closure component in response to the actuation input (col. 20, lines 14-19).

Claim 15: Lafontaine et al. discloses the claimed device except for a collapse actuator when actuated moves the closure component from the non-collapsed position to the collapsed position.

Redmond et al. teaches a collapse actuator **22** when actuated moves the closure component **26** from the non-collapsed position to the collapsed position (Figures 1-3). It would have been obvious to one of ordinary skill in the art to provide a collapse actuator, as taught by Redmond et al., to Lafontaine et al. in order to minimize the chance of arterial penetration and effective closure of the wound.

Claim 16: Lafontaine et al. discloses an elongate member **334** having a distal end disconnectably connected to a distal end of the closure component **344**, the elongate member **334** being configured to move the distal end of the closure component **344** to a more proximal position to collapse the closure component **344** under proximally directed force applied to the elongate member **334** (Figures 34A-34C and col. 17, lines 31-43).

Art Unit: 3734

Claims 17-20: Lafontaine et al. discloses the claimed device, including the elongate member being received within a distal aperture in the closure component (Figure 34A), except for a deformable hook at the distal end of the elongate member, the deformable hook being located distal of the distal aperture when the closure component is in the non-collapsed position, the deformable hook moving a distal end of the closure component to a more proximal position to collapse the closure component under proximally directed force applied to the elongate member, and the deformable hook deforming to pass through the distal aperture in the closure component.

Redmond et al. teaches a deformable hook **22** at the distal end of an elongate member **20** that grasps a closure component **26** and moves a distal end of the closure component to a more proximal position to collapse the closure component under proximally directed force applied to the elongate member and wherein the deformable hook is located distal of the distal aperture in the closure component **22** when the closure component is in the non-collapsed form, the deformable hook **22** capable of deforming to pass through the distal aperture in the closure component **22** after the closure component **22** has moved to the collapsed position under continued application of proximally directed force on the elongate member **20** (Figures 1-4, col. 26-37). It would have been obvious to one of ordinary skill in the art to provide a deformable hook at the distal end of the elongate member, as taught by Redmond et al., to Lafontaine et al., since it was known in the art that a deformable hooks are flexible and useful in manipulating devices in blood vessels and moving through the distal ends of elongate members.

Art Unit: 3734

Claim 21: Lafontaine et al. discloses the elongate member **334** comprising a wire (Figure 34A).

Claims 22-23: Lafontaine et al. discloses the wire **334** comprising a frangible, mechanically releasable connection to the distal end of the closure component (col. 20, lines 14-19).

Claims 24 and 25: Lafontaine et al. discloses the closure component is formed of a biocompatible, bioabsorbable material (col. 4, lines 62-67).

Claim 27: Lafontaine et al. discloses inserting the closure component **344** with an elongate delivery member **334**, the closure component **344** being disposed at a distal end of the delivery member **334** (col. 17, lines 31-38).

Claim 28: Lafontaine et al. discloses disconnecting the closure component **344** from the distal end of the delivery member **334** (col. 18, lines 30-35).

Claim 29: Lafontaine et al. discloses exerting proximally directed force on the delivery member **334** after collapsing the collapsible pile (col. 18, lines 2-12).

Claim 30: Lafontaine et al. discloses moving a distal end of the closure component **344** toward a proximal end thereof (col. 17, lines 40-45).

Claim 31: Lafontaine et al. discloses the tissue engaging hooks being comprised of tissue piercing hooks that pierce the tissue when the tissue is engaged (col. 17, lines 38-40).

Claim 32: Lafontaine et al. discloses the opening **332** is in a body cavity defined by media and having adventitia adjacent thereto and wherein withdrawing comprises



Art Unit: 3734

withdrawing the tissue engaging hooks proximally past the media to engage the adventitia (Figures 34A-34C and col. 17, lines 27-42).

Claims 40-41: Lafontaine et al. discloses the fibrous tissue engaging members and the backing being disposed on a same surface of the closure component comprising an exterior surface of the closure component (Figure 34A).

### ***Response to Arguments***

3. Applicant's arguments with respect to Claims 1-10,13, and 15-39 have been considered but are moot in view of the new ground(s) of rejection.

### ***Conclusion***

4. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of

Art Unit: 3734

the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Diane Yabut whose telephone number is (571) 272-6831. The examiner can normally be reached on M-F: 9AM-4PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hayes can be reached on (571) 272-4959. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

DY



MICHAEL J. HAYES  
SUPERVISORY PATENT EXAMINER